|
Hepatitis, Toxic
|
0.300 |
Biomarker
|
disease |
CTD_human |
"Serum microRNA signatures as ""liquid biopsies"" for interrogating hepatotoxic mechanisms and liver pathogenesis in human."
|
28545106 |
2017 |
|
Drug-Induced Liver Disease
|
0.300 |
Biomarker
|
phenotype |
CTD_human |
"Serum microRNA signatures as ""liquid biopsies"" for interrogating hepatotoxic mechanisms and liver pathogenesis in human."
|
28545106 |
2017 |
|
Hepatitis, Drug-Induced
|
0.300 |
Biomarker
|
disease |
CTD_human |
"Serum microRNA signatures as ""liquid biopsies"" for interrogating hepatotoxic mechanisms and liver pathogenesis in human."
|
28545106 |
2017 |
|
Drug-Induced Acute Liver Injury
|
0.300 |
Biomarker
|
disease |
CTD_human |
"Serum microRNA signatures as ""liquid biopsies"" for interrogating hepatotoxic mechanisms and liver pathogenesis in human."
|
28545106 |
2017 |
|
Chemical and Drug Induced Liver Injury
|
0.300 |
Biomarker
|
disease |
CTD_human |
"Serum microRNA signatures as ""liquid biopsies"" for interrogating hepatotoxic mechanisms and liver pathogenesis in human."
|
28545106 |
2017 |
|
Chemically-Induced Liver Toxicity
|
0.300 |
Biomarker
|
disease |
CTD_human |
"Serum microRNA signatures as ""liquid biopsies"" for interrogating hepatotoxic mechanisms and liver pathogenesis in human."
|
28545106 |
2017 |
|
Pancreatic carcinoma
|
0.030 |
Biomarker
|
disease |
BEFREE |
MicroRNA-191 promotes pancreatic cancer progression by targeting USP10.
|
25168367 |
2014 |
|
Malignant neoplasm of pancreas
|
0.030 |
Biomarker
|
disease |
BEFREE |
MicroRNA-191 promotes pancreatic cancer progression by targeting USP10.
|
25168367 |
2014 |
|
Carcinogenesis
|
0.050 |
Biomarker
|
phenotype |
BEFREE |
miR-191 promotes tumorigenesis of human colorectal cancer through targeting C/EBPβ.
|
25784653 |
2015 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
MicroRNA-191 (miR-191), a small non-coding RNA, is involved in disease development and cancer diagnosis and prognosis.
|
25784653 |
2015 |
|
Primary malignant neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
MicroRNA-191 (miR-191), a small non-coding RNA, is involved in disease development and cancer diagnosis and prognosis.
|
25784653 |
2015 |
|
Kidney Diseases
|
0.010 |
AlteredExpression
|
group |
BEFREE |
miR-191 and miR-151-3p exhibited significantly higher and lower intrarenal expression in all six subtypes of kidney diseases compared to controls. miR-19b was upregulated in three subtypes, and miR-30a-5p and miR-150 were downregulated in two and four subtypes, respectively.
|
26481277 |
2015 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
MicroRNA-191 acts as a tumor promoter by modulating the TET1-p53 pathway in intrahepatic cholangiocarcinoma.
|
28194813 |
2017 |
|
Intrahepatic Cholangiocarcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
MicroRNA-191 acts as a tumor promoter by modulating the TET1-p53 pathway in intrahepatic cholangiocarcinoma.
|
28194813 |
2017 |
|
Primary cholangiocarcinoma of intrahepatic biliary tract
|
0.010 |
Biomarker
|
disease |
BEFREE |
MicroRNA-191 acts as a tumor promoter by modulating the TET1-p53 pathway in intrahepatic cholangiocarcinoma.
|
28194813 |
2017 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
miR-191 was overexpressed in 93 cases of ESCC, compared with adjacent normal tissues, and miR-191 expression was significantly related to differentiation, depth of invasion, TNM stage, lymph node metastasis, and distant metastasis of tumor.
|
29047233 |
2017 |
|
Neoplasm Metastasis
|
0.040 |
AlteredExpression
|
phenotype |
BEFREE |
miR-191 was overexpressed in 93 cases of ESCC, compared with adjacent normal tissues, and miR-191 expression was significantly related to differentiation, depth of invasion, TNM stage, lymph node metastasis, and distant metastasis of tumor.
|
29047233 |
2017 |
|
Liver diseases
|
0.010 |
AlteredExpression
|
group |
BEFREE |
MicroRNA-191 has recently been reported to be abnormally expressed in hepatocellular carcinoma and other liver diseases in the regulation of important cellular processes.
|
29769640 |
2019 |
|
Cholangiocarcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
miR-191 Inhibition Induces Apoptosis Through Reactivating Secreted Frizzled-Related Protein-1 in Cholangiocarcinoma.
|
30235453 |
2018 |
|
Androgen-Insensitivity Syndrome
|
0.010 |
Biomarker
|
disease |
BEFREE |
MiR-191 was increased in the plasma of AIS patients, OGD/R HUVECs, and the plasma and brain of MCAO rats.
|
31064890 |
2019 |
|
Osteosarcoma
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
MiR-191-5p was upregulated in OS tissues, which was related to poor prognosis of OS patients.
|
31114985 |
2019 |
|
Osteosarcoma of bone
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
MiR-191-5p was upregulated in OS tissues, which was related to poor prognosis of OS patients.
|
31114985 |
2019 |
|
Childhood Osteosarcoma
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
MiR-191-5p was upregulated in OS tissues, which was related to poor prognosis of OS patients.
|
31114985 |
2019 |
|
Malignant Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
MicroRNA-191 (miR-191) has been identified as being upregulated in several types of cancers, and plays the role of oncogene.
|
31335671 |
2019 |
|
Glioblastoma
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
MiR-191 over-expression was sufficient to promote human glioblastoma cells growth in vivo and in vitro.
|
31364126 |
2019 |